摘要
目的探讨阿维A辅助治疗复发性尖锐湿疣临床效果及安全性。方法选取本院近年来收治复发性尖锐湿疣患者70例,随机分为对照组和阿维A组,每组各35例;其中对照组采用常规对症治疗;阿维A组在对照组治疗基础上,加用阿维A口服治疗;比较两组患者临床复发率,治疗前后血清细胞因子水平及不良反应发生率等。结果阿维A组患者治疗后1个月、3个月及6个月临床复发率均显著低于对照组(P<0.05);对照组和阿维A组患者治疗后IL-4、IL-10及IFN-γ等细胞因子水平均显著优于治疗前,且阿维A组患者细胞因子水平改善程度均显著优于于对照组(P<0.05);阿维A组患者皮肤不适及口干发生率均显著高于对照组,但皮肤溃烂发生率显著低于对照组(P<0.05)。结论阿维A辅助治疗复发性尖锐湿疣可有效降低临床复发风险,改善机体细胞因子水平,提高机体免疫力,且无严重不良反应。
Objective To investigate clinical efficacy and security of Avi A associated treatment on re -current genital warts .Methods 70 patients with recurrent genital warts were chosen in recent years in our hos-pital and randomly divided into two groups including control group (35 patients) with conventional symptomatic treatment and Avi A group (35 patients) with Avi A orally treatment;and the clinical relapse rate , cytokines levels in serum before and after treatment and incidence of adverse reaction of both groups were compared . Results The clinical relapse rate of Avi A group was lower than control group in 1 month, 3 months and 6 months after treatment(P&lt;0.05).The cytokines levels in serum after treatment of both groups was significant better than before treatment(P&lt;0.05).The improving degree of Avi A group after treatnemtn was significant higher than control group ( P&lt;0.05 ) .The incidence of skin irritation , dry mouth of Avi A group was higher than control group(P&lt;0.05).The incidence of skin ulcers of Avi A group was lower than control group (P&lt;0.05).Conclusion Avi A associated treatment on recurrent genital warts can efficiently reduce the risk of clinical recurrence , improve cytokines levels , higher body immunity , and has no serious adverse reactions .
出处
《中国实用医药》
2014年第2期21-22,共2页
China Practical Medicine
关键词
复发性尖锐湿疣
临床效果
安全性
阿维A
Avi A
Recurrent genital warts
Clinical efficacy
Security